Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 1, 1999
Last updated: December 3, 2013
Last verified: May 1999

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with surgery and/or radiation therapy may kill more tumor cells.

PURPOSE: This randomized phase III trial is studying surgery followed by different regimens of combination chemotherapy given together with radiation therapy and/or additional surgery to compare how well they work in treating patients with soft tissue sarcoma.

Condition Intervention Phase
Childhood Malignant Fibrous Histiocytoma of Bone
Biological: dactinomycin
Drug: carboplatin
Drug: cyclophosphamide
Drug: epirubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: vincristine sulfate
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: brachytherapy
Radiation: radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 400
Study Start Date: January 1995
Study Completion Date: December 2009
  Show Detailed Description


Ages Eligible for Study:   up to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed primary soft tissue sarcoma:

    • Rhabdomyosarcoma
    • Non-rhabdomyosarcoma
    • Soft tissue primitive neuroectodermal tumor (PNET)
    • Extraosseous Ewing's sarcoma



  • Under 18

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified



  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • Prior primary surgery allowed


  • No other prior therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002898

United Kingdom
Institute of Child Health
Bristol, England, United Kingdom, BS2 8AE
Sponsors and Collaborators
Societe Internationale d'Oncologie Pediatrique
Study Chair: M. C. G. Stevens, MD Institute of Child Health at University of Bristol
  More Information

Additional Information:
Publications: Identifier: NCT00002898     History of Changes
Other Study ID Numbers: CDR0000065228, SIOP-MMT-95, EU-96035
Study First Received: November 1, 1999
Last Updated: December 3, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
embryonal childhood rhabdomyosarcoma
alveolar childhood rhabdomyosarcoma
pleomorphic childhood rhabdomyosarcoma
mixed childhood rhabdomyosarcoma
embryonal-botryoid childhood rhabdomyosarcoma
nonmetastatic childhood soft tissue sarcoma
childhood fibrosarcoma
childhood synovial sarcoma
childhood malignant hemangiopericytoma
childhood liposarcoma
childhood alveolar soft-part sarcoma
childhood leiomyosarcoma
childhood neurofibrosarcoma
childhood angiosarcoma
childhood epithelioid sarcoma
childhood malignant fibrous histiocytoma of bone
childhood malignant mesenchymoma
previously untreated childhood rhabdomyosarcoma
childhood desmoplastic small round cell tumor
localized Ewing sarcoma/peripheral primitive neuroectodermal tumor

Additional relevant MeSH terms:
Histiocytoma, Benign Fibrous
Histiocytoma, Malignant Fibrous
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Fibrous Tissue
Sarcoma processed this record on March 03, 2015